M
Maicon Falavigna
Researcher at Universidade Federal do Rio Grande do Sul
Publications - 108
Citations - 6354
Maicon Falavigna is an academic researcher from Universidade Federal do Rio Grande do Sul. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 27, co-authored 89 publications receiving 4227 citations. Previous affiliations of Maicon Falavigna include McMaster University & Pontifícia Universidade Católica do Rio Grande do Sul.
Papers
More filters
Medication labels from the perspective of Brazilian health professionals: difficulties, level of satisfaction, and proposed improvements
Cassia Garcia Moraes,Tatiane da Silva Dal Pizzol,Maicon Falavigna,Lisana Reginini Sirtori,Fernanda da Cruz,Guilherme,Webster,Emilia da Silva Pons +7 more
TL;DR: Moraes et al. as discussed by the authors proposed a social responsibility department, Hospital Moinhos de Vento (HMV), Porto Alegre, RS, Brazil.
Journal ArticleDOI
Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective
Frederico José Bighetti Magro,Aline Pires Barbosa,A. Taminato,Celina Borges Migliavaca,Pasquale Federico,Renata Tebyriçá,J.C Cancado,Pedro Giavina-Bianchi,Maicon Falavigna +8 more
TL;DR: In this article , the authors compared the costs of omalizumab and dupilumab for treating severe allergic asthma patients from the perspective of the Brazilian private healthcare system.
Journal ArticleDOI
BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan
Regis Goulart Rosa,Julia Regazzini Spinardi,Kristen E Allen,Josélia Larger Manfio,Cintia Laura Pereira de Araujo,Mírian Cohen,Caroline Cabral Robinson,Daniel Sganzerla,Diogo Ferreira,Emanuel Maltempi de Souza,Jaqueline Carvalho de Oliveira,Daniela Fiori Gradia,Ana Paula Carneiro Brandalize,Gabriela Almeida Kucharski,Fernando Pedrotti,Cristina de Oliveira Rodrigues,Moe H. Kyaw,Graciela Del Carmen Morales Castillo,Amit Kumar Srivastava,John M McLaughlin,Maicon Falavigna +20 more
TL;DR: This study aims to evaluate, in a real-world setting in Brazil, the effectiveness of Pfizer-BioNTech BNT162b2 against symptomatic CO VID-19 and COVID-19-related complications across diverse populations.